フマリルアセトアセターゼ
関連文献

St-Louis M, Tanguay RM (1997). “Mutations in the fumarylacetoacetate hydrolase gene causing hereditary tyrosinemia type I: overview”. Hum. Mutat. 9 (4):  291–9. doi:10.1002/(SICI)1098-1004(1997)9:4<291::AID-HUMU1>3.0.CO;2-9. PMID 9101289.
Phaneuf D, Lambert M, Laframboise R, Mitchell G, Lettre F, Tanguay RM (1992). “Type 1 hereditary tyrosinemia. Evidence for molecular heterogeneity and identification of a causal mutation in a French Canadian patient”. J. Clin. Invest. 90 (4):  1185–92. doi:10.1172/JCI115979. PMC 443158. PMID 1401056. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC443158/.
Tanguay RM, Valet JP, Lescault A, Duband JL, Laberge C, Lettre F, Plante M (1990). “Different molecular basis for fumarylacetoacetate hydrolase deficiency in the two clinical forms of hereditary tyrosinemia (type I)”. Am. J. Hum. Genet. 47 (2):  308–16. PMC 1683717. PMID 2378356. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1683717/.
Laberge C, Grenier A, Valet JP, Morissette J (1990). “Fumarylacetoacetase measurement as a mass-screening procedure for hereditary tyrosinemia type I”. Am. J. Hum. Genet. 47 (2):  325–8. PMC 1683713. PMID 2378358. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1683713/.
Kvittingen EA, Halvorsen S, Jellum E (1983). “Deficient fumarylacetoacetate fumarylhydrolase activity in lymphocytes and fibroblasts from patients with hereditary tyrosinemia”. Pediatr. Res. 17 (7):  541–4. doi:10.1203/00006450-198307000-00005. PMID 6622096.
Kvittingen EA, Jellum E, Stokke O (1982). “Assay of fumarylacetoacetate fumarylhydrolase in human liver-deficient activity in a case of hereditary tyrosinemia”. Clin. Chim. Acta 115 (3):  311–9. doi:10.1016/0009-8981(81)90244-8. PMID 7296877.
Hahn SH, Krasnewich D, Brantly M, Kvittingen EA, Gahl WA (1995). “Heterozygosity for an exon 12 splicing mutation and a W234G missense mutation in an American child with chronic tyrosinemia type 1”. Hum. Mutat. 6 (1):  66–73. doi:10.1002/humu.1380060113. PMID 7550234.
St-Louis M, Poudrier J, Phaneuf D, Leclerc B, Laframboise R, Tanguay RM (1995). “Two novel mutations involved in hereditary tyrosinemia type I”. Hum. Mol. Genet. 4 (2):  319–20. doi:10.1093/hmg/4.2.319. PMID 7757089.
Kato S, Sekine S, Oh SW, Kim NS, Umezawa Y, Abe N, Yokoyama-Kobayashi M, Aoki T (1995). “Construction of a human full-length cDNA bank”. Gene 150 (2):  243–50. doi:10.1016/0378-1119(94)90433-2. PMID 7821789.
Rootwelt H, Berger R, Gray G, Kelly DA, Coşkun T, Kvittingen EA (1994). “Novel splice, missense, and nonsense mutations in the fumarylacetoacetase gene causing tyrosinemia type 1”. Am. J. Hum. Genet. 55 (4):  653–8. PMC 1918286. PMID 7942842. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1918286/.
Rootwelt H, Brodtkorb E, Kvittingen EA (1994). “Identification of a frequent pseudodeficiency mutation in the fumarylacetoacetase gene, with implications for diagnosis of tyrosinemia type I”. Am. J. Hum. Genet. 55 (6):  1122–7. PMC 1918441. PMID 7977370. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1918441/.
Rootwelt H, Chou J, Gahl WA, Berger R, Coşkun T, Brodtkorb E, Kvittingen EA (1994). “Two missense mutations causing tyrosinemia type 1 with presence and absence of immunoreactive fumarylacetoacetase”. Hum. Genet. 93 (6):  615–9. doi:10.1007/BF00201558. PMID 8005583.
Grompe M, St-Louis M, Demers SI, al-Dhalimy M, Leclerc B, Tanguay RM (1994). “A single mutation of the fumarylacetoacetate hydrolase gene in French Canadians with hereditary tyrosinemia type I”. N. Engl. J. Med. 331 (6):  353–7. doi:10.1056/NEJM199408113310603. PMID 8028615.
St-Louis M, Leclerc B, Laine J, Salo MK, Holmberg C, Tanguay RM (1994). “Identification of a stop mutation in five Finnish patients suffering from hereditary tyrosinemia type I”. Hum. Mol. Genet. 3 (1):  69–72. doi:10.1093/hmg/3.1.69. PMID 8162054.
Grompe M, al-Dhalimy M (1993). “Mutations of the fumarylacetoacetate hydrolase gene in four patients with tyrosinemia, type I”. Hum. Mutat. 2 (2):  85–93. doi:10.1002/humu.1380020205. PMID 8318997.
Labelle Y, Phaneuf D, Leclerc B, Tanguay RM (1993). “Characterization of the human fumarylacetoacetate hydrolase gene and identification of a missense mutation abolishing enzymatic activity”. Hum. Mol. Genet. 2 (7):  941–6. doi:10.1093/hmg/2.7.941. PMID 8364576.
Labelle Y, Puymirat J, Tanguay RM (1993). “Localization of cells in the rat brain expressing fumarylacetoacetate hydrolase, the deficient enzyme in hereditary tyrosinemia type 1”. Biochim. Biophys. Acta 1180 (3):  250–6. doi:10.1016/0925-4439(93)90046-4. PMID 8422430.
Ploos van Amstel JK, Bergman AJ, van Beurden EA, Roijers JF, Peelen T, van den Berg IE, Poll-The BT, Kvittingen EA, Berger R (1996). “Hereditary tyrosinemia type 1: novel missense, nonsense and splice consensus mutations in the human fumarylacetoacetate hydrolase gene; variability of the genotype-phenotype relationship”. Hum. Genet. 97 (1):  51–9. doi:10.1007/bf00218833. PMID 8557261.